Valeant Pharmaceuticals International, Inc. Posted losses of -6.59% in the Last Trade

Andrew Cummings
April 6, 2017

03/07/2017 - Valeant Pharmaceuticals International, Inc. had its "hold" rating reiterated by analysts at Deutsche Bank. The stock was sold at an average price of $11.00, for a total value of $199,258,752.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Several analysts recently commented on the stock.

The stock subtracted in the prior trading session by -6.59%, closing at the stock price of $9.5. As it began its asset sale, Valeant suggested that investors could expect about $8 billion worth of asset dumps, but so far the company has only raised about $2.1 billion. The disclosure for this purchase can be found here. Also, insider Valueact Capital Master Fund, bought 3,000,000 shares of the business's stock in a transaction dated Tuesday, March 14th. The correct version of this story can be read at Royal Bank of Canada reduced their price target on Valeant Pharmaceuticals Intl to $21.00 in a report on Wednesday, March 1st. BTIG Research restated a "neutral" rating on shares of Valeant Pharmaceuticals Intl in a research note on Friday, March 3rd. The stock gained a consensus recommendation of 2.33 on Zacks Investment Research where the scale runs from 1 to 5, 1 representing Strong buy and 5 showing Strong Sell. The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has "Underweight" rating given on Wednesday, January 4 by Piper Jaffray. The stock is now trading with a distance of 20-Day Simple Moving Average (SMA20) of -8.61%.

Valeant Pharmaceuticals Intl (NYSE:VRX) last announced its earnings results on Tuesday, February 28th. The sell-side analysts are projecting earnings per share of $0.95 for the next fiscal quarter. According to their predictions High & Low revenue estimates are 25.84 Billion and 23.96 Billion respectively. Valeant Pharmaceuticals Intl has a 52 week low of $13.56 and a 52 week high of $50.18.

EPS growth for this year is -714.90% and EPS growth for next year is expected to reach at 21.85%.

Stock is now moving with a negative distance from the 200 day simple moving average of approximately -50.94%, and has a poor year to date (YTD) performance of -34.57% which means the stock is constantly subtracting to its value from the previous fiscal year end price. Hedge funds and other institutional investors own 64.34% of the company's stock. US Bancorp DE now owns 5,745 shares of the specialty pharmaceutical company's stock valued at $141,000 after buying an additional 3,361 shares during the last quarter. Finally, Independent Advisor Alliance purchased a new stake in Valeant Pharmaceuticals Intl during the fourth quarter valued at $344,000. Kistler Tiffany Companies LLC increased its stake in Valeant Pharmaceuticals Intl by 95.5% in the third quarter. The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has "Buy" rating given on Tuesday, September 29 by Nomura. The Relative Volume value measured for Valeant Pharmaceuticals International, Inc.

While taking a look at financials, we can look at a number of key indicators about Valeant Pharmaceuticals International, Inc.

In case of Revenue Estimates, 5 analysts have provided their consensus Average Revenue Estimates for Valeant Pharmaceuticals International, 297.08 Million. The Firm is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Other reports by iNewsToday